HBM Partners AG
Axel Bolte has served as a member of PTC’s board of directors since December 2003. Since March 2003, Mr. Bolte has served as investment advisor at HBM Partners AG, a provider of investment advisory services in the life sciences industry. From March 2001 to February 2003, Mr. Bolte was an investment manager of NMT New Medical Technologies AG, a Swiss venture capital company focused on life sciences. Prior to joining NMT New Medical Technologies AG, Mr. Bolte served as a scientist at Serono SA, a biotechnology company. He currently serves on the board of several public and private biotech companies, including Newron Pharmaceuticals SpA (SWX Swiss Exchange: NWRN; Milan, Italy), Nabriva Therapeutics Forschungs GmbH (Vienna, Austria), Lux Biosciences, Inc. (Jersey City, NJ) and MPex Pharmaceuticals, Inc. (San Diego, CA).

Mr. Bolte holds an MBA from the University of St. Gallen (HSG). He studied biochemistry and organic chemistry at the Swiss Federal Institute of Technology in Zurich (ETH) and at the University of Cambridge, UK, where he focused on the synthesis of complex natural products of marine origin.